Literature DB >> 11874216

Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature.

Terence A Ketter1, Joseph R Calabrese.   

Abstract

Management of bipolar disorder has traditionally emphasized the acute treatment of mania. Although acute treatment of mania is a critical aspect of care, this emphasis has tended to overshadow other important phases of bipolar disorder, such as depression, hypomania, and subsyndromal symptoms. We offer a reconceptualization of bipolar disorder that highlights unmet needs and the importance of differential spectra of efficacy. In this reconceptualization, bipolar disorder can be viewed as an aberration of mood, behavior, and cognition from baseline (euthymia). "Below baseline" is characterized by depression and subsyndromal depression. "Above baseline" is characterized by mania, mixed states, hypomania, and subsyndromal mood elevation. In contrast to the treatment options for mania, the options for depression are limited. This new nomenclature emphasizes the need to develop mood stabilizers that possess the ability to stabilize mood "from below baseline," either alone or in combination with other agents. In this article, the treatment options for bipolar disorder, with a focus on depression and rapid cycling, are discussed according to this new conceptualization of management from below and above baseline.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874216     DOI: 10.4088/jcp.v63n0210

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  25 in total

1.  A critical appraisal of treatments for bipolar disorder.

Authors:  Andrew A Nierenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 3.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Authors:  David E Kemp; Martha Schinagle; Keming Gao; Carla Conroy; Stephen J Ganocy; Faramarz Ismail-Beigi; Joseph R Calabrese
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

6.  Interleaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid have different effects on corticolimbic activity.

Authors:  Xingbao Li; Raffaella Ricci; Charles H Large; Berry Anderson; Ziad Nahas; Daryl E Bohning; Mark S George
Journal:  Psychopharmacology (Berl)       Date:  2010-03-02       Impact factor: 4.530

Review 7.  Pharmacotherapy of bipolar depression: an update.

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

Review 8.  Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.

Authors:  Anna Grunze; Benedikt L Amann; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

10.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.